Semaglutide

FDA-Approved moleculeCompounded form not FDA-approved

Also known as: Ozempic, Wegovy, GLP-1 agonist

GLP-1 receptor agonist

How it works: Mimics the GLP-1 hormone the gut releases after eating. It acts on receptors that influence appetite and the feeling of fullness, and slows how quickly the stomach empties, which can reduce overall food intake.
Known risks: Commonly reported: nausea, vomiting, diarrhea, constipation. Boxed warning for thyroid C-cell tumors based on rodent studies; pancreatitis and gallbladder events have been reported.
Contraindications: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; known hypersensitivity.
Drug interactions: May affect absorption of oral medications due to delayed gastric emptying; additive risk of low blood sugar when combined with insulin or sulfonylureas.

Citations

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (2021) · PMID 33567185

This information is educational only and is not medical advice. A licensed provider makes all clinical decisions. Diadara provides no dosing, reconstitution, or administration guidance.

Start an assessment